Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study
Frontiers in Pharmacology · 10.01.2023 · 13
DOI: 10.3389/fphar.2022.1025947 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 10.01.2023. Verfasst von Jieun Kang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ilsan Paik Hospital, Goyang-si, South Korea. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and ICT, South Korea.
Abstract (Originalsprache)
Background
Pirfenidone, an antifibrotic medication approved for the treatment of idiopathic pulmonary fibrosis (IPF), often requires dose reduction owing to adverse events. In this study, we evaluated if pirfenidone’s reduced dose has any impact on clinical outcomes in patients with IPF.
Methods
We used the data of a prospective post-marketing study of pirfenidone conducted at 10 hospitals in South Korea from 2014 to 2017. Dose reduction was defined when the pirfenidone dose was temporarily or permanently reduced to manage adverse events or when the treatment dose failed to reach the standard dose. Study patients were classified based on the most frequently administered dose during 48-week follow-up—1800 mg, 1,200 mg, and <1,200 mg/days. The following clinical outcomes were compared between the groups: death, hospitalization, acute exacerbation, pulmonary function decline, and changes in severity of dyspnea and cough.
Results
The median follow-up duration in all 143 patients was 11 months. During the study period, 70.6% experienced at least one dose reduction. Patients treated with standard-dose pirfenidone tended to be young and had the lowest diffusing capacity. Pulmonary function changes did not differ depending on the pirfenidone dose. The three groups were not significantly different in terms of the proportion of death, hospitalization, and acute exacerbation. The symptom changes were also similar between the groups.
Conclusion
Reduced doses did not negatively impact clinical outcomes compared with the standard-dose pirfenidone in patients with IPF. Dose reduction may be a useful method to manage adverse events while maintaining therapeutic efficacy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ilsan Paik Hospital, Goyang-si, South Korea.
- Samsung Medical Center, Department of Pulmonary and Critical Care Medicine, Sungkyunkwan University School of Medicine, Seoul, South Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea.
- Department of Internal Medicine, Chonnam National University Medical School and Hwasun Hospital, Hwasun, South Korea.
- Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Research Center for Pulmonary Disorders, Jeonbuk National University Medical School and Hospital, Jeonju, South Korea.
- Division of Respiratory-Allergy and Clinical Immunology, Department of Internal Medicine, Konkuk University Medical Center, Seoul, South Korea.
Förderung
- Ministry of Science and ICT, South Korea
Zitieren
APA
Kang, J., Chung, M. P., Park, M. S., Oh, I. J., Lee, H. B., Kim, Y. W., Park, J. S., Uh, S. T., Kim, Y. S., Jegal, Y., & Song, J. W. (2023). Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1025947
Vancouver
Kang J, Chung MP, Park MS, Oh IJ, Lee HB, Kim YW, et al. Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study. Frontiers in Pharmacology. 2023;13. doi:10.3389/fphar.2022.1025947
BibTeX
@article{Kang2023,
author = {Kang, Jieun and Chung, Man Pyo and Park, Moo Suk and Oh, In Jae and Lee, Heung Bum and Kim, Young Whan and Park, Jong Sun and Uh, Soo Taek and Kim, Yun Seong and Jegal, Yangjin and Song, Jin Woo},
title = {Clinical outcomes of dose modification during pirfenidone treatment for IPF: A nationwide post-marketing surveillance study},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {13},
doi = {10.3389/fphar.2022.1025947}
}
EUVIMED